
sourcing the best research evidence in ophthalmology
Ranibizumab Therapy for Diabetic Macular Edema (RISE AND RIDE)
October 1, 2013
Clinical trial
Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.
Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, Schlottmann PG, Rundle AC, Zhang J, Rubio RG, Adamis AP, Ehrlich JS, Hopkins JJ.
Main finding: Ranibizumab rapidly and sustainably improved vision and reduced risk of further vision loss in patients with DME, with low rates of ocular and non-ocular harm.
- Purpose: To evaluate the efficacy and safety of intravitreal ranibizumab in diabetic macular edema,
- Study type: Randomized controlled trial
- Condition: Diabetic Macular Edema
Participants: Type 1 or 2 DM, Ci-DME , VA 20/40-20/320 (6/12-6/96) and central subfield thickness ≥275 μm
- n=377 (RISE), 382 (RIDE)
Intervention:
Groups:
- Group 1: Sham
- Group 2: Ranibizumab 0.3mg
- Group 3: Ranibizumab 0.5mg
Outcome | Groups | Sham | RAN 0.3mg | RAN 0.5mg |
---|---|---|---|---|
Gain of ≥15 letters (Proportion) at 2 years | RISE | 18.1% | 44.8% | 39.2% |
RIDE | 12.3% | 33.6% | 45.7% | |
Gain of ≥15 letters (Proportion) at 3 years | RISE | 19.2% | 36.8% | 40.2% |
RIDE | 22.0% | 51.2% | 41.6% |
April 1, 2012
Clinical trial
Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.
Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ, Rubio RG, Ehrlich JS.
Main finding: Ranibizumab rapidly and sustainably improved vision and reduced risk of further vision loss in patients with DME, with low rates of ocular and non-ocular harm.
- Purpose: To evaluate the efficacy and safety of intravitreal ranibizumab in diabetic macular edema,
- Study type: Randomized controlled trial
- Condition: Diabetic Macular Edema
Participants: Type 1 or 2 DM, Ci-DME , VA 20/40-20/320 (6/12-6/96) and central subfield thickness ≥275 μm
- n=377 (RISE), 382 (RIDE)
Intervention:
Groups:
- Group 1: Sham
- Group 2: Ranibizumab 0.3mg
- Group 3: Ranibizumab 0.5mg
Outcome | Groups | Sham | RAN 0.3mg | RAN 0.5mg |
---|---|---|---|---|
Gain of ≥15 letters (Proportion) at 2 years | RISE | 18.1% | 44.8% | 39.2% |
RIDE | 12.3% | 33.6% | 45.7% | |
Gain of ≥15 letters (Proportion) at 3 years | RISE | 19.2% | 36.8% | 40.2% |
RIDE | 22.0% | 51.2% | 41.6% |
Source Archive